Xenomics announces license with Asuragen for NPM1 leukemia diagnostics.
Publication Date: 01-SEP-07
Publication Title: BIOTECH Patent News
Format: Online
Company: Xenomics Inc.

Read this article now
Try Goliath Business News - FREE!
You can view this article PLUS...

  • Over 5 million business articles
  • Hundreds of the most trusted magazines, newswires, and journals (see list)
  • Premium business information that is timely and relevant
  • Unlimited Access

Now for a Limited Time, try Goliath Business News
Free for 7 Days!

Tell Me More   Terms and Conditions

Purchase this article for $4.95

Description

Xenomics, Inc. (New York, NY) has granted Asuragen, Inc. co-exclusive worldwide rights to incorporate NPM1 technology into Asuragen's molecular diagnostic products. Under the terms of this agreement, Asuragen will have the right to develop, manufacture and market products for the diagnosis, stratification and monitoring of patients with Acute Myeloid Leukemia (AML).

AML is a clinically heterogeneous disease with an estimated 13,500 new cases per year in the United States and 200,000 worldwide. The disease subgrouping by karyotypic abnormalities indicates patient prognosis. However, in almost half of AML cases the karyotype...



More articles from BIOTECH Patent News
University of Southern California obtains United States patent., September 01, 2007
Celtrix obtains United States patent., September 01, 2007
Monsanto obtains United States patent., September 01, 2007
ProChon obtains United States patent., September 01, 2007
Degussa obtains United States patent., September 01, 2007

Looking for additional articles?
Click here to search our database of over 3 million articles.